The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is a huge mover today! The stock decreased 5.01% or $0.22 on November 30, hitting $4.17. About 104,543 shares traded hands. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 53.40% since April 27, 2016 and is downtrending. It has underperformed by 58.62% the S&P500.
The move comes after 9 months negative chart setup for the $268.29M company. It was reported on Nov, 30 by Barchart.com. We have $4.00 PT which if reached, will make NASDAQ:ADAP worth $10.73 million less.
Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Ratings Coverage
Out of 2 analysts covering Adaptimmune Therapeutics PLC (NASDAQ:ADAP), 1 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 50% are positive. Adaptimmune Therapeutics PLC has been the topic of 2 analyst reports since February 25, 2016 according to StockzIntelligence Inc. The firm earned “Buy” rating on Thursday, February 25 by Citigroup. Bank of America downgraded Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) on Monday, October 24 to “Underperform” rating.
According to Zacks Investment Research, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.”
More news for Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) were recently published by: Marketwatch.com, which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015. Quotes.Wsj.com‘s article titled: “DOW JONES, A NEWS CORP COMPANY” and published on November 29, 2014 is yet another important article.
ADAP Company Profile
Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.